Rallybio
Clinical-stage biotechnology company focused on discovering and developing biologic therapies for rare diseases, with an emphasis on complement dysregulation and hematology. The organization pursues protein-engineered therapeutics (including antibody mimetics and monoclonal antibodies), preclinical and early clinical development, translational pharmacology, regulatory strategy, manufacturing/CMC, and partnership-driven business development.
Industries
Nr. of Employees
small (1-50)
Products
RLYB116
Once-weekly, small-volume, subcutaneously administered C5 inhibitor developed as an antibody-mimetic fusion protein to inhibit terminal complement activation and leverage albumin-binding for extended half-life.
RLYB332
Long-acting monoclonal antibody targeting matriptase-2 (MTP-2) designed to increase hepcidin levels for treatment of diseases with ineffective erythropoiesis and iron overload.
RLYB114
Preclinical C5-targeted protein scaffold conjugated to polyethylene glycol intended for intravitreal administration to address complement-driven ophthalmic diseases.
RLYB116
Once-weekly, small-volume, subcutaneously administered C5 inhibitor developed as an antibody-mimetic fusion protein to inhibit terminal complement activation and leverage albumin-binding for extended half-life.
RLYB332
Long-acting monoclonal antibody targeting matriptase-2 (MTP-2) designed to increase hepcidin levels for treatment of diseases with ineffective erythropoiesis and iron overload.
RLYB114
Preclinical C5-targeted protein scaffold conjugated to polyethylene glycol intended for intravitreal administration to address complement-driven ophthalmic diseases.
Expertise Areas
- Complement biology and therapeutics
- Biologic (protein) engineering
- Monoclonal antibody development
- Preclinical and early-phase clinical development
Key Technologies
- Antibody-mimetic fusion proteins
- Small protein affinity scaffolds
- Monoclonal antibodies
- PEG conjugation (PEGylation)
News & Updates
Poster presentation on a long-acting anti-matriptase-2 antibody as a potential therapy for iron overload diseases presented at the 66th American Society of Hematology Meeting & Exposition (December 2024).
Poster describing prophylactic administration of an HPA-1a-specific antibody preventing fetal/neonatal alloimmune thrombocytopenia in mice; presented at ASH 2024.
Pharmacometrics study addressing pregnancy dosing using target-mediated drug disposition modeling for a recombinant human monoclonal antibody.
Preclinical study demonstrating prevention of fetal/neonatal alloimmune thrombocytopenia in mice after prophylactic administration of HPA-1a–specific antibodies.
Poster presentation on a long-acting anti-matriptase-2 antibody as a potential therapy for iron overload diseases presented at the 66th American Society of Hematology Meeting & Exposition (December 2024).
Poster describing prophylactic administration of an HPA-1a-specific antibody preventing fetal/neonatal alloimmune thrombocytopenia in mice; presented at ASH 2024.
Pharmacometrics study addressing pregnancy dosing using target-mediated drug disposition modeling for a recombinant human monoclonal antibody.
Preclinical study demonstrating prevention of fetal/neonatal alloimmune thrombocytopenia in mice after prophylactic administration of HPA-1a–specific antibodies.